Minireview: computer simulations of blood pressure regulation by the renin-angiotensin system.

Gene targeting experiments in mice have been used by us and others to test whether quantitative changes in gene expression in the renin-angiotensin system affect blood pressure. Surprisingly, these studies showed that blood pressure does not change with mild quantitative changes in the expression of the angiotensin converting enzyme (ACE). Yet, ACE inhibitors are widely used for the treatment of hypertension. This apparent paradox motivated us to develop a simple computer simulation, which qualitatively reconciled the paradox. We have now improved the simulation by including blood pressure as an explicit variable and by adding the kallikrein-kinin system and feedback control of plasma renin via plasma angiotensin II levels. The new simulation now matches quantitative aspects of the experimental data and suggests that a decrease in bradykinin plays an important role in the increased risk of diabetic nephropathy associated with genetically determined higher levels of ACE activity. This emphasizes that the value of these types of simulation lies in the thoughts that they provoke rather than in their ability to replicate experimental data.

[1]  Helen V. Firth,et al.  Down syndrome (trisomy 21) , 2005 .

[2]  S. John,et al.  Molecular phenotyping for analyzing subtle genetic effects in mice: Application to an angiotensinogen gene titration , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[3]  B. L. Langille,et al.  Maternal cardiovascular changes during pregnancy and postpartum in mice. , 2002, American journal of physiology. Heart and circulatory physiology.

[4]  Y. Ohashi,et al.  Effect of captopril or imidapril on the progression of diabetic nephropathy in Japanese with type 1 diabetes mellitus: a randomized controlled study (JAPAN-IDDM). , 2002, Diabetes research and clinical practice.

[5]  M. Marre,et al.  Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[6]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[7]  H. Parving,et al.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. , 2001, The New England journal of medicine.

[8]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[9]  J. Chan,et al.  Contribution of gene polymorphisms in the renin-angiotensin system to macroangiopathy in patients with diabetic nephropathy. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  J. Knowles,et al.  Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice. , 2001, The Journal of clinical investigation.

[11]  N. Chaturvedi Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. , 2001, Annals of internal medicine.

[12]  G. Chatellier,et al.  Prognostic value of angiotensin-I converting enzyme I/D polymorphism for nephropathy in type 1 diabetes mellitus: a prospective study. , 2001, Journal of the American Society of Nephrology : JASN.

[13]  Ali G. Gharavi,et al.  Molecular Mechanisms of Human Hypertension , 2001, Cell.

[14]  J. Kvetny,et al.  Randomized placebo-controlled trial of perindopril in normotensive, normoalbuminuric patients with type 1 diabetes mellitus. , 2001, QJM : monthly journal of the Association of Physicians.

[15]  H. S. Kim,et al.  Importance of quantitative genetic variations in the etiology of hypertension. , 2000, Kidney international.

[16]  D. Vaughan,et al.  Angiotensin-converting enzyme insertion/deletion polymorphism modulates the human in vivo metabolism of bradykinin. , 2000, Circulation.

[17]  D. Ganten,et al.  Regulation of renin: new evidence from cultured cells and genetically modified mice , 2000, Journal of Molecular Medicine.

[18]  Bruce H. R. Wolffenbuttel,et al.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy , 2000, The Lancet.

[19]  S. Yusuf,et al.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[20]  D. Stec,et al.  Novel mechanism of hypertension revealed by cell-specific targeting of human angiotensinogen in transgenic mice. , 1999, Physiological genomics.

[21]  Hyung-Suk Kim,et al.  Homeostasis in Mice with Genetically Decreased Angiotensinogen Is Primarily by an Increased Number of Renin-producing Cells* , 1999, The Journal of Biological Chemistry.

[22]  M. Esler,et al.  Recent insight into therapy of congestive heart failure: focus on ACE inhibition and angiotensin-II antagonism. , 1999, Journal of the American College of Cardiology.

[23]  G. Heusch,et al.  Infarct size reduction by AT1-receptor blockade through a signal cascade of AT2-receptor activation, bradykinin and prostaglandins in pigs. , 1998, Journal of the American College of Cardiology.

[24]  J. Connell,et al.  Angiotensin converting enzyme gene polymorphisms and renal disease , 1998, Current opinion in nephrology and hypertension.

[25]  O. Carretero,et al.  Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. , 1997, The Journal of clinical investigation.

[26]  John Quackenbush,et al.  A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. , 1997, The Journal of clinical investigation.

[27]  H. S. Kim,et al.  Angiotensin-converting enzyme gene mutations, blood pressures, and cardiovascular homeostasis. , 1997, Hypertension.

[28]  F. Cambien,et al.  Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study , 1996, BMJ.

[29]  R. Lifton Molecular Genetics of Human Blood Pressure Variation , 1996, Science.

[30]  M. Capecchi,et al.  Mice lacking angiotensin-converting enzyme have low blood pressure, renal pathology, and reduced male fertility. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[31]  J. Charles Jennette,et al.  Male–female differences in fertility and blood pressure in ACE-deficient mice , 1995, Nature.

[32]  J. Hodgin,et al.  A noninvasive computerized tail-cuff system for measuring blood pressure in mice. , 1995, Hypertension.

[33]  H. S. Kim,et al.  Genetic control of blood pressure and the angiotensinogen locus. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[34]  A. Krolewski,et al.  Genetic Predisposition to Diabetic Nephropathy: Evidence for a Role of the Angiotensin I–Converting Enzyme Gene , 1994, Diabetes.

[35]  D. Campbell,et al.  Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. , 1994, Hypertension.

[36]  F. Cambien,et al.  Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. , 1994, Diabetes.

[37]  Steven C. Hunt,et al.  Molecular basis of human hypertension: Role of angiotensinogen , 1992, Cell.

[38]  R J Jarrett,et al.  Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus: a twenty-three year follow-up study. , 1992, Kidney international.

[39]  R. Carey,et al.  Recruitment of renin gene-expressing cells in adult rat kidneys. , 1990, The American journal of physiology.

[40]  P Corvol,et al.  An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. , 1990, The Journal of clinical investigation.

[41]  M. Seikaly,et al.  Endogenous angiotensin concentrations in specific intrarenal fluid compartments of the rat. , 1990, The Journal of clinical investigation.

[42]  R. Ward Familial aggregation and genetic epidemiology of blood pressure , 1990 .

[43]  S. Kreiner,et al.  Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus. , 1987, British medical journal.

[44]  S. L. Jindal,et al.  Clinical Physiology of Acid—Base and Electrolyte Disorders. , 1978 .

[45]  J. Taylor The hypertension detection and follow-up program: a progress report. , 1977, Circulation research.

[46]  D. Weatherall,et al.  The Principles of Human Biochemical Genetics , 1975 .

[47]  J. Laragh Hypertension manual : mechanisms, methods, management , 1974 .

[48]  G. Pickering,et al.  Hypertension. Definitions, natural histories and consequences. , 1972, The American journal of medicine.